AbDrop™: Fully Human Antibodies Discovery: Increased Diversity, Validated Candidates in Just 3 Months! 詳しくはこちら

New Small-Scale Expression Packages: RushMab- Ready in just 8 days! 詳しくはこちら

Biointron Insights: Antibody Industry Outlook (2026 Insights, Trends & Analysis) 詳しくはこちら

Biointron Insights: Antibody Industry Report (Q2 2025 Insights, Trends & Analysis) 詳しくはこちら

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis) 詳しくはこちら

Biointron x Antibody Society Webinar: Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening 詳しくはこちら

Biointron - リコンビナント抗体発現/開発サービス

Antibody Antibody Antibody

カスタムサービス&プロダクト品

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Antibodies Delivered Annually

Why you should choose us

  • 先進的抗体ソリューション

    私たちは抗体の発現、開発、最適化に注力し、先進的な自動化生産ラインを持ち、競争力のある価格と効率的なリードタイムを提供できます。

  • ユニークな細胞株を商品化

    私たちはECACCからライセンスされたCHOK1BN細胞株の商業化に関する排他的な再ライセンス権を保有しています。

  • グローバルな協力体制

    私たちの2,000+のグローバルなバイオテクノロジー企業や製薬企業とのパートナーシップになり、そして、国際的な臨床段階での共同の進歩と結びついています。

  • 信頼と所有権

    私たちは、お客様に提供した抗体の所有権を守り、機密情報の保持をお約束します。

Antibody

Biointronとの協力により、最適化された効率的で経済的かつ最高水準のカスタム抗体ソリューションを提供します。

About Biointron

Biointronは2012年に設立され、ISO 9001:2015認証を取得し、抗体の発見、開発、最適化分野のハイテク企業です。


Biointronは、リーディングな高スループットの再組み合わせ抗体/タンパク質発現および開発サービスプロバイダーです。遺伝子配列から抗体の精製まで、わずか2週間で行います。Biointronは、1700+のバイオテクノロジー企業や製薬企業に数万種類の再組み合わせ抗体を提供しています。

詳しくはこちら 詳しくはこちら

お客様からの声

Biointronのパートナーやクライアントから、Biointronの専門知識がもたらす変革のインパクトについて学びましょう。

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

ニュース一覧

Biointron Insights: Antibody Industry Outlook (2026 Insights, Trends & Analysis)

Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs have been approved by China, United States, Europe, and Australia.

2026-02-01
Roundup of Antibody Biotech Deals in January 2026

January 2026 deal activity leaned heavily toward bispecific, trispecific, and ADC assets, particularly in oncology and immunology, alongside steady investment in AI-enabled target discovery and antibody engineering platforms. Several of the month’s largest transactions focused on late preclinical and early clinical programs, pointing to continued pharma interest in differentiated antibody modalities with well-defined mechanisms as the year gets underway.

2026-02-06
HEK293 vs CHO Cells for Antibody Expression: Mechanistic Differences, Product Quality, and Strategic Implications

This article examines HEK293 and CHO across biological characteristics, productivity, glycosylation, product integrity, and application-specific strategy, integrating findings from recent comparative studies.

2026-01-30
Biointron Sets a New High in Cybersecurity Performance with 2026 CyberVadis “Mature” Rating

On February 22, 2026, Biointron successfully completed its latest third-party cybersecurity assessment conducted by CyberVadis, achieving an overall score of 923/1000 at the Mature security capability level, which is the highest level in the CyberVadis rating framework.

2026-02-25
Biointron Awarded 2025 Scientist.com Supplier Performance Recognition Award

Biointron, a specialized antibody contract research organization (CRO), has been awarded the 2025 Scientist.com Supplier Performance Recognition Award for outstanding performance in delivering drug discovery research services throughScientist.com’sglobal R&D sourcing platform.Scient

2025-12-17
New Publication Highlights Biointron’s AbDrop Platform for Plasma Cell-Based Antibody Discovery

The development of Biointron’s AbDrop, a scalable microfluidics-based platform for high-throughput identification and characterization of plasma cell-derived antibodies, was recently described in a study published in mAbs.

2025-12-05
Immuno-Oncology Summit 2025

Time: August 11 - 13, 2025
Location: Philadelphia, Pennsylvania
Booth: #1

Discovery on Target 2025

Time: September 22 - 25, 2025
Location: Boston, MA
Booth: #410

Festival of Biologics Europe 2025

Time: September 30 - October 2, 2025
Location: Basel, Switzerland
Booth: #713

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。